KYN-101

Cat. No.:	HY-134217		
CAS No.:	2247950-73	-6	
Molecular Formula:	C ₂₂ H ₁₉ FN ₆		
Molecular Weight:	386.42		
Target:	Aryl Hydroc	arbon Re	ceptor
Pathway:	Immunolog	y/Inflam	mation
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

SOLVENT & SOLUBILITY

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.5879 mL	12.9393 mL	25.8786 mL
	5 mM	0.5176 mL	2.5879 mL	5.1757 mL
	10 mM	0.2588 mL	1.2939 mL	2.5879 mL

BIOLOGICAL ACTIV	ΊΤΥ	
Description	KYN-101 is a potent, seld shows anti-cancer activ	ective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 $ity^{[1]}$.
In Vitro) decreases the CYP1A1 mRNA expression in IDO ^{high} samples ^[1] . ntly confirmed the accuracy of these methods. They are for reference only.
In Vivo		; daily for 12 days) shows anti-cancer activity in mice ^[1] . ntly confirmed the accuracy of these methods. They are for reference only. 6-8 weeks, C57BL/6J mice (B16IDO tumor-bearing mice) ^[1]
	Dosage:	10 mg/kg
	Administration:	P.o.; daily for 12 days

Product Data Sheet

ΝH

N-N

ΗN

Result:	Reduced tumor growth in B16IDO tumor-bearing mice and combination of KYN-101 and
	anti-PD-1 led to improved tumor growth delay and extended survival in CT26 models.

REFERENCES

[1]. Campesato LF, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020 Aug 11;11(1):4011.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA